Drugs / AGS-16C3F
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01672775 | Jul 2012 → Feb 2017 | clear cell renal carcinoma, papillary renal cell carcinoma | Agensys, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02639182 | May 2016 → Oct 2020 | renal cell carcinoma | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS-16C3F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01672775 ↗ |
| Known as | ADC AGS-16C3F | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594455 ↗ |
| Known as | Ags-16c3f (anti-enpp3 antibody) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594455 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT01672775 ↗ |
| Target | ENPP3 | “Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 binding agent” CHEMBL4594455 ↗ |